• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Elanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600

    8/26/25 6:15:00 PM ET
    $BHLB
    $BRKL
    $ELAN
    $SPGI
    Banks
    Finance
    Savings Institutions
    Finance
    Get the next $BHLB alert in real time by email

    NEW YORK, Aug. 26, 2025 /PRNewswire/ -- Elanco Animal Health Inc. (NYSE:ELAN) will replace Sarepta Therapeutics Inc. (NASD: SRPT) in the S&P MidCap 400, and Sarepta Therapeutics will replace Brookline Bancorp Inc. (NASD: BRKL) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, September 2. S&P SmallCap 600 constituent Berkshire Hills Bancorp Inc. (NYSE:BHLB) is acquiring Brookline Bancorp in a deal expected to be completed soon, pending final closing conditions. Post merger, Berkshire Hills Bancorp will remain in the S&P SmallCap 600 with a name and ticker change to Beacon Financial Corp. (NYSE:BBT).

    Following is a summary of the changes that will take place prior to the open of trading on the effective date:

    Effective Date 

    Index Name 

    Action 

    Company Name 

    Ticker 

    GICS Sector 

    September 2, 2025 

    S&P MidCap 400 

    Addition 

    Elanco Animal Health 

    ELAN 

    Health Care 

    September 2, 2025 

    S&P MidCap 400

    Deletion 

    Sarepta Therapeutics 

    SRPT 

    Health Care 

    September 2, 2025 

    S&P SmallCap 600 

    Addition 

    Sarepta Therapeutics 

    SRPT 

    Health Care 

    September 2, 2025 

    S&P SmallCap 600

    Deletion

    Brookline Bancorp

    BRKL

    Financials

    For more information about S&P Dow Jones Indices, please visit www.spdji.com

    ABOUT S&P DOW JONES INDICES

    S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

    S&P Dow Jones Indices is a division of S&P Global (NYSE:SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com.

    FOR MORE INFORMATION:

    S&P Dow Jones Indices

    [email protected] 

    Media Inquiries

    [email protected] 

    Cision View original content:https://www.prnewswire.com/news-releases/elanco-animal-health-set-to-join-sp-midcap-400-sarepta-therapeutics-to-join-sp-smallcap-600-302539403.html

    SOURCE S&P Dow Jones Indices

    Get the next $BHLB alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BHLB
    $BRKL
    $ELAN
    $SPGI

    CompanyDatePrice TargetRatingAnalyst
    Elanco Animal Health Incorporated
    $ELAN
    10/7/2025$24.00Neutral → Overweight
    Analyst
    S&P Global Inc.
    $SPGI
    10/1/2025$540.00Buy
    Seaport Research Partners
    Sarepta Therapeutics Inc.
    $SRPT
    9/22/2025$50.00Market Perform → Outperform
    BMO Capital Markets
    Sarepta Therapeutics Inc.
    $SRPT
    7/29/2025$22.00Underweight → Equal Weight
    Barclays
    Sarepta Therapeutics Inc.
    $SRPT
    7/29/2025$13.00Mkt Perform
    Bernstein
    Sarepta Therapeutics Inc.
    $SRPT
    7/29/2025$37.00Perform → Outperform
    Oppenheimer
    Sarepta Therapeutics Inc.
    $SRPT
    7/29/2025$24.00Underweight → Neutral
    Analyst
    Sarepta Therapeutics Inc.
    $SRPT
    7/29/2025$5.00Sell
    H.C. Wainwright
    More analyst ratings

    $BHLB
    $BRKL
    $ELAN
    $SPGI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    S&P Global to Launch Innovative Crypto Ecosystem Index, a New Way to Combine Cryptocurrencies and Crypto-Linked Equities

    NEW YORK, Oct. 7, 2025 /PRNewswire/ -- S&P Global (NYSE:SPGI) today announced plans to expand its S&P Dow Jones Indices ("S&P DJI") crypto index offering with the launch of the S&P Digital Markets 50 Index. Dinari, a leading provider of tokenized U.S. public securities, has collaborated with S&P Global on the index design and will create a token tracking the benchmark. The index is designed to track a wide range of companies and digital assets connected to the crypto ecosystem, combining cryptocurrencies and publicly traded crypto-linked equities into one index. "Cryptocurrenc

    10/7/25 9:00:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2025 World Muscle Society Congress

    Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present at the 30th Annual Congress of the World Muscle Society (WMS) 2025 Congress, taking place Oct. 7-11, 2025, in Vienna, Austria. Sarepta presentations will include results from several studies in the delandistrogene moxeparvovec clinical development program, as well as a real-world evidence study of pulmonary function in advanced-stage patients with Duchenne muscular dystrophy treated with casimersen. Further, Sarepta will present results from the EMERGENE phase 3 study on the expression of SGCB and safety following bidridistrogene xeboparvovec treatment in patients with LGMD2E

    10/3/25 8:30:00 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    S&P Global Schedules Third Quarter 2025 Earnings Announcement and Conference Call for Thursday, October 30, 2025

    NEW YORK, Oct. 2, 2025 /PRNewswire/ -- S&P Global's (NYSE:SPGI) third quarter 2025 results will be issued on Thursday, October 30, 2025 via news release at approximately 7:15 a.m. Eastern Daylight Time. The news release will be available at www.spglobal.com. Martina Cheung, President and CEO; Eric Aboaf, Chief Financial Officer; and Mark Grant, Senior Vice President, Investor Relations and Treasurer, will host a conference call and webcast at 8:30 a.m. Eastern Daylight Time on October 30, 2025 to discuss the Company's third quarter 2025 financial results. The presentation is open to all interested parties and may include forward-looking information. The presenters' slides, supplemental deck

    10/2/25 4:00:00 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $BHLB
    $BRKL
    $ELAN
    $SPGI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for AMONDYS 45 issued to SAREPTA THERAPS INC

    Submission status for SAREPTA THERAPS INC's drug AMONDYS 45 (SUPPL-8) with active ingredient CASIMERSEN has changed to 'Approval' on 07/11/2024. Application Category: NDA, Application Number: 213026, Application Classification: Labeling

    7/12/24 4:40:36 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    June 20, 2024 - FDA Expands Approval of Gene Therapy for Patients with Duchenne Muscular Dystrophy

    For Immediate Release: June 20, 2024 Today, the U.S. Food and Drug Administration expanded the approval of Elevidys (delandistrogene moxeparvovec-rokl), a gene therapy for the treatment of Duchenne muscular dystrophy (DMD) for ambulatory and non-ambulatory individuals 4 years of age and older with DMD with a confirmed mutation in the DMD gene.  Elevidys was previously approved under accelerated approval for amb

    6/20/24 5:24:42 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYONDYS 53 issued to SAREPTA THERAPS INC

    Submission status for SAREPTA THERAPS INC's drug VYONDYS 53 (SUPPL-11) with active ingredient GOLODIRSEN has changed to 'Approval' on 06/04/2024. Application Category: NDA, Application Number: 211970, Application Classification: Labeling

    6/5/24 4:41:31 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHLB
    $BRKL
    $ELAN
    $SPGI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Elanco Animal Health upgraded by Analyst with a new price target

    Analyst upgraded Elanco Animal Health from Neutral to Overweight and set a new price target of $24.00

    10/7/25 8:46:24 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Seaport Research Partners initiated coverage on S&P Global with a new price target

    Seaport Research Partners initiated coverage of S&P Global with a rating of Buy and set a new price target of $540.00

    10/1/25 9:39:03 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Sarepta Therapeutics upgraded by BMO Capital Markets with a new price target

    BMO Capital Markets upgraded Sarepta Therapeutics from Market Perform to Outperform and set a new price target of $50.00

    9/22/25 8:19:54 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHLB
    $BRKL
    $ELAN
    $SPGI
    SEC Filings

    View All

    SEC Form 15-12G filed by Brookline Bancorp Inc.

    15-12G - BROOKLINE BANCORP INC (0001049782) (Filer)

    9/12/25 12:37:12 PM ET
    $BRKL
    Savings Institutions
    Finance

    Amendment: SEC Form SCHEDULE 13G/A filed by Sarepta Therapeutics Inc.

    SCHEDULE 13G/A - Sarepta Therapeutics, Inc. (0000873303) (Subject)

    9/8/25 11:06:08 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Brookline Bancorp Inc.

    S-8 POS - BROOKLINE BANCORP INC (0001049782) (Filer)

    9/2/25 8:58:16 AM ET
    $BRKL
    Savings Institutions
    Finance

    $BHLB
    $BRKL
    $ELAN
    $SPGI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Officer Modi Rajeev A.

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    10/7/25 4:47:22 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    10/7/25 4:46:37 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP and CFO Vanhimbergen Robert M was granted 109,857 shares (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    10/3/25 5:10:36 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHLB
    $BRKL
    $ELAN
    $SPGI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kurzius Lawrence Erik bought $211,000 worth of shares (20,000 units at $10.55), increasing direct ownership by 22% to 111,459 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    3/11/25 5:13:30 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hoover R David bought $272,558 worth of shares (25,000 units at $10.90) (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    3/7/25 4:21:21 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Harrington Michael J bought $51,974 worth of shares (3,500 units at $14.85), increasing direct ownership by 5% to 81,094 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    8/26/24 5:05:35 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHLB
    $BRKL
    $ELAN
    $SPGI
    Leadership Updates

    Live Leadership Updates

    View All

    Bentley Systems Set to Join S&P MidCap 400 and Western Union to Join S&P SmallCap 600

    NEW YORK, Oct. 1, 2025 /PRNewswire/ -- Bentley Systems Inc. (NASD: BSY) will replace Western Union Co. (NYSE:WU) in the S&P MidCap 400, and Western Union will replace Mr. Cooper Group Inc. (NASD: COOP) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, October 6. Rocket Companies Inc. (NYSE:RKT) acquired Mr. Cooper Group in a deal that closed today, October 1. Western Union's market capitalization is more representative of the small-cap market space. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name        Action Company Name Ticker GICS Sector October 6, 2025   S&P MidCap

    10/1/25 6:03:00 PM ET
    $BSY
    $RKT
    $SPGI
    Computer Software: Prepackaged Software
    Technology
    Finance: Consumer Services
    Finance

    Carbon Data Open Protocol (CDOP) Coalition Unveils Open-Source Data Model at Climate Week NYC to Facilitate and Scale Carbon Markets

    37 organizations including Isometric, Verra, South Pole, and Kita commit to continue supporting the adoption and development of the Carbon Data Open Protocol (CDOP) Version 1.0 Open-source data schema for project location, details & approach addresses carbon market fragmentationDeveloped in alignment with, and building upon, other data standardization initiatives, including the G20-led Common Carbon Credit Data Model (CCCDM), the CAD Trust, and the UNFCCC (relating to Article 6)NEW YORK, Sept. 23, 2025 /PRNewswire/ -- Today at Climate Week NYC a growing coalition of carbon market participants announced the release of Version 1.0 of the Carbon Data Open Protocol (CDOP) structure to help facil

    9/23/25 7:00:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    ACM Research Set to Join S&P SmallCap 600

    NEW YORK, Sept. 22, 2025 /PRNewswire/ -- ACM Research Inc. (NASD: ACMR) will replace WK Kellogg Co. (NYSE:KLG) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, September 26. The Ferrero Group is acquiring WK Kellogg in a deal expected to close soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector Sept 26, 2025 S&P SmallCap 600 Addition ACM Research ACMR Information Technology Sept 26, 2025 S&P SmallCap 600 Deletion WK Kellogg KLG Consumer Staples ABOUT S&P DOW JONES INDICES S&P Dow Jones Indices i

    9/22/25 6:16:00 PM ET
    $ACMR
    $KLG
    $SPGI
    Industrial Machinery/Components
    Technology
    Packaged Foods
    Consumer Staples

    $BHLB
    $BRKL
    $ELAN
    $SPGI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sarepta Therapeutics Inc.

    SC 13G/A - Sarepta Therapeutics, Inc. (0000873303) (Subject)

    11/13/24 10:27:59 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Brookline Bancorp Inc.

    SC 13G/A - BROOKLINE BANCORP INC (0001049782) (Subject)

    11/12/24 5:09:10 PM ET
    $BRKL
    Savings Institutions
    Finance

    Amendment: SEC Form SC 13G/A filed by Brookline Bancorp Inc.

    SC 13G/A - BROOKLINE BANCORP INC (0001049782) (Subject)

    11/12/24 10:03:30 AM ET
    $BRKL
    Savings Institutions
    Finance

    $BHLB
    $BRKL
    $ELAN
    $SPGI
    Financials

    Live finance-specific insights

    View All

    S&P Global Schedules Third Quarter 2025 Earnings Announcement and Conference Call for Thursday, October 30, 2025

    NEW YORK, Oct. 2, 2025 /PRNewswire/ -- S&P Global's (NYSE:SPGI) third quarter 2025 results will be issued on Thursday, October 30, 2025 via news release at approximately 7:15 a.m. Eastern Daylight Time. The news release will be available at www.spglobal.com. Martina Cheung, President and CEO; Eric Aboaf, Chief Financial Officer; and Mark Grant, Senior Vice President, Investor Relations and Treasurer, will host a conference call and webcast at 8:30 a.m. Eastern Daylight Time on October 30, 2025 to discuss the Company's third quarter 2025 financial results. The presentation is open to all interested parties and may include forward-looking information. The presenters' slides, supplemental deck

    10/2/25 4:00:00 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Elanco Confirms Date and Conference Call for Third Quarter 2025 Financial Results Announcement

    GREENFIELD, Ind., Oct. 1, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its third quarter 2025 financial results on Wednesday, November 5, 2025. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/de

    10/1/25 8:00:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    S&P 500 Q2 2025 Buybacks Declines 20% Amidst Uncertainty to $235 Billion From Q1 2025's Record $293 Billion; Q3 2025 Expenditures Expected to Increase Back to Near Record Levels

    S&P 500 Q2 2025 buybacks were $234.6 billion, as the expenditure declined 20.1% from the record Q1 2025 $293.5 billion and was down 0.6% from Q2 2024's $235.9 billionThe 12-month June 2025 expenditure was $997.8 billion and was up 13.7% from the 12-month June 2024 expenditure of $877.5 billion Utilities was the only sector to increase spending, up 16.5% over Q1 2025, Health Care reduced spending by 39.3%, Information Technology by 16.3% and Communication Services by 15.0%The net buyback 1% tax reduced Q2 2025 operating earnings, which are set to post a quarterly earnings record, by 0.39% and As Reported GAAP by 0.42%, as the 12-month cost was 0.42% and 0.45%, respectivelyNEW YORK, Sept. 17,

    9/17/25 9:00:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance